Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5141 Target Snapshot

Cytochrome P450 26A1 · SINGLE PROTEIN · Homo sapiens

257Compounds
35Assays
3Approved Drugs
345.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Cytochrome P450 26A1 shows clinical signal disease relevance led by acne. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt O43174. Start with acne, then reuse UniProt O43174 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with acne, then reuse UniProt O43174 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
acne

Cytochrome P450 26A1 shows clinical signal disease relevance led by acne. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with acne because it currently carries clinical signal support. Linked drugs include TALAROZOLE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cytochrome P450 26A1 as ChEMBL target CHEMBL5141, mapped to UniProt O43174. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cytochrome P450 26A1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL5141
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
O43174
Cytochrome P450 26A1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Cytochrome P450 26A1 is the right protein anchor across sources, using UniProt O43174 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why acne is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCytochrome P450 26A1
UniProt AccessionO43174
Component TypeProtein
Sequence Length497 aa

Cytochrome P450 26A1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Cytochrome P450 26A1, mapped to UniProt O43174. Sequence length is 497 aa.

Mapped IDO43174
Review nameCytochrome P450 26A1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Cytochrome P450 26A1 shows clinical signal disease relevance led by acne. 2 more disease programs remain visible in the same review block.

Clinical signal Phase II
acne
1 linked drug · 1 direct · 1 efficacy
Linked drugTALAROZOLE
Clinical signal Phase II
psoriasis
1 linked drug · 1 direct · 1 efficacy
Linked drugTALAROZOLE
Clinical signal Phase I
inflammation
1 linked drug · 1 direct · 1 efficacy
Linked drugTALAROZOLE
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with acne because it currently carries clinical signal support. Linked drugs include TALAROZOLE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseacne
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

3
Approved
2
Phase II
Assay Mix

Activity Type Distribution

IC50345.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1831092 9.52 IC50 0.3 Preclinical
CHEMBL1831083 9.46 IC50 0.35 Preclinical
CHEMBL208443 8.89 IC50 1.3 Preclinical
CHEMBL205862 8.85 IC50 1.4 Preclinical
CHEMBL207304 8.8 IC50 1.6 Preclinical
CHEMBL57765 8.62 IC50 2.4 Preclinical
CHEMBL1766005 8.52 IC50 3.0 Preclinical
CHEMBL1766007 8.52 IC50 3.0 Preclinical
CHEMBL207486 8.52 IC50 3.0 Preclinical
CHEMBL368448 8.48 IC50 3.3 Preclinical
Distribution

pChEMBL Value Distribution

47
5.0
37
5.5
39
6.0
19
6.5
38
7.0
20
7.5
33
8.0
10
8.5
2
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

KETOCONAZOLE
CHEMBL157101
Approved 1981
Assay Landscape

Assay Landscape

35
Total Assays
187
Tested Compounds
3
Assay Types
Binding — 28 assays, 187 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 16 89 5.7
single protein format 8 62 6.8
microsome format 4 36 7.4
Functional — 6 assays, 29 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 5 25 7.5
microsome format 1 4 7.3
ADME — 1 assays, 22 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 22 4.9

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine